HRMY241115P40000
- 7.10
- +4.70+195.83%
Harmony Biosciences Newsroom
Harmony Biosciences Is Maintained at Overweight by Cantor Fitzgerald
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Maintains Target Price $28
Cantor Fitzgerald Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $58
Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $59
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Harmony Biosciences Analyst Ratings
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Announces Target Price $28
Raymond James Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $40
Harmony Biosciences Price Target Announced at $40.00/Share by Raymond James
Harmony Biosciences Analyst Ratings
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $52
Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $56
A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $44 to $56
Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target
Harmony Biosciences Analyst Ratings
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52